RNS Announcements

All the posts published.

EMV Capital leads £4.2m investment round in Scottish 5G and SATCOM leader

Nov 29, 2022
-
News, RNS Announcements
NetScientific plc (“NetScientific” or the “Company”) EMV Capital leads £4.2m investment round in Scottish 5G and SATCOM leader   Sofant Technologies also announces contract with Fortune Global 500 defence company   London, UK – 29 November 2022: NetScientific plc (AIM: NSCI), the active international holding company which invests in, develops, and commercialises life sciences/healthcare, sustainability, and technology companies, announces that it has joined an…

PDS Biotech Third Quarter 2022 Financial Results and Business Update

Nov 14, 2022
-
PDS Biotechnology, RNS Announcements
NetScientific plc (“NetScientific” or the “Company”) PDS Biotech Third Quarter 2022 Financial Results and Business Update NetScientific Plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, reports that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has announced its financial results for the quarter ended 30 September 2022.   Highlights    PDS0101 Lead Drug Candidate VERSATILE-002 Phase 2 Clinical…

Board Change

Nov 9, 2022
-
RNS Announcements
NetScientific plc (“NetScientific” or “NSCI” or the “Company” or the “Group”) Board Change London, UK – 9 November 2022: NetScientific Plc (AIM: NSCI), the active international holding company, which invests in, develops, and commercialises life sciences/healthcare, sustainability, and technology companies, today announces that John Clarkson is relinquishing his executive status and becoming Non-Executive Chairman of the Company with immediate effect. John joined the NetScientific Board…

PDS Biotech Announces Presentation of Data for PDS0101 at Society for Immunotherapy of Cancer

Nov 7, 2022
-
PDS Biotechnology, RNS Announcements
NetScientific plc (“NetScientific” or the “Company”) PDS Biotech Update PDS Biotech announces presentation of data for PDS0101 at Society for Immunotherapy of Cancer   NetScientific Plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, is delighted to report that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has announced upcoming presentations of clinical data from two Phase 2 clinical…

PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers

Oct 27, 2022
-
PDS Biotechnology, RNS Announcements
RNS REACH NetScientific PLC ("NetScientific", the "Group" or the "Company") PDS Update PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers   NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), announced expanded interim data in the Phase 2 clinical trial…

EMV Capital Secures Investment in Leading Domestic Heat Efficiency Company Ventive

Oct 20, 2022
-
RNS Announcements
RNS REACH NetScientific PLC (“NetScientific” or the “Company”) EMV Capital Secures Investment in Leading Domestic Heat Efficiency Company Ventive London, UK – 20 October 2022:  NetScientific PLC (AIM: NSCI), the active international holding company, which invests in, develops and commercialises life sciences/healthcare, sustainability and technology companies, announces that its subsidiary EMV Capital has led and advised on a £2.5m investment round in domestic heat…

PDS completes End-of-Phase 2 meeting with FDA

Oct 3, 2022
-
News, PDS Biotechnology, RNS Announcements
  NetScientific plc ("NetScientific", the "Group" or the "Company")   PDS completes End-of-Phase 2 meeting with FDA   NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for PDS0101 in…

Interim Results for the six months ended 30 June 2022

Oct 3, 2022
-
News, RNS Announcements
  NetScientific plc   (“NetScientific” or “NSCI” or the “Company” or the “Group”)   Interim Results for the six months ended 30 June 2022   London, UK – 30 September 2022: NetScientific Plc (AIM: NSCI), the active international holding company, which invests in, develops and commercialises life sciences/healthcare, sustainability and technology companies, today announces its interim results for the six months ended 30 June…

PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance

Aug 25, 2022
-
News, RNS Announcements
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), announced that it has entered into a debt financing agreement led by Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”)…

Completion of acquisition of 30% stake in Vortex Biotech Holdings (Vortex) and appointment of new Vortex CEO

Aug 16, 2022
-
News, RNS Announcements
NetScientific plc ("NetScientific", the "Group" or the "Company") Completion of acquisition of 30% stake in Vortex Biotech Holdings (Vortex)   and appointment of new Vortex CEO   To drive commercial opportunities and develop an industry leading solution   NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, is pleased to announce, further to its announcement of 6 May 2022,…
RNS Announcements Archives - NetScientific